1Nesheim M.Thrombin and fibrlnolysis[J]. Chest,2003,124: 33S.
2Braze GJ Jr, Miletich JP. Protein Z-dependent regulation of coagulation [J]. Thromb Haemost,2001,86:8.
3Brouwers GJ, Leebeek FW, Tanck MW, et al. Association between thrombin activatable fibrinolysis inhibitor (TAFI) and clinical outcome in patients with unstable angina pectoris[J] .Thromb Haemost,2003,90:92.
4Leebeek FW, Goor MP, Guimaraes AH, et al. High fimctional levels of thrombin-activatable fibrinolysis inhibitor are associated with an in creased risk of first ischemic stroke[J] .J Thromb Haemost,2005,3:2211.
5Kitagawa N, Yano Y, Gabazza EC,et al. Different metabolic correlations of thrombin-activatable fibrinolysis inhibitor and plasminogen activator in- hibitor-1 in non-obese type-2 diabetic patients [ J ]. Diabetes Res Clin Pract,2006,137:150.
6Malyszko J, Malyszko JS, Hryszko T, et al.Thrombin activatable fibfinolysis inhibitor(TAFI)and markers of endothelial cell injury in dialyzed patients with diabetic n ephropathy[J]. Thromb Haemost,2004, 91:480.
